Ulviprubart

尤扑拜单抗

Report date: 2023/03/17 14:22:06

Base Information

Drug NameUlviprubart
Drug Alias NameABC008ABC-008
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionKiller cell lectin-like receptor subfamily G member 1 antagonists
TargetsKiller cell lectin-like receptor subfamily G member 1
Therapy Area/IndicationsMyositis, Inclusion BodyLeukemia, Large Granular Lymphocytic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[7] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesAbcuro Inc
China Registration ClassN/A

Develop Information

Active CompaniesAbcuro Inc
Inactive CompaniesN/A
Active IndicationsMyositis, Inclusion BodyLeukemia, Large Granular Lymphocytic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A